Bizarre Patents
A method for inducing cats to exercise consists of directing a beam of invisible light produced by a hand-held laser apparatus onto the floor or wall.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7309502 | Pharmaceutical compositions for treating and saving and the method for the preparation thereof The present invention relates to a pharmaceutical composition and the method for the preparation thereof. The composition comprises 1.5˜6.9% (w/v) of one or more substances selected from sodium chloride, sodium bicarbonate, potassium chloride, magnesium sulfate, ca... | 12/18/2007 |
| 7101846 | Methods and compositions for optimization of oxygen transport by cell-free systems Compositions, and methods of use thereof, for use as blood substitute products comprise aqueous mixtures of oxygen-carrying and non-oxygen carrying plasma expanders and methods for the use thereof. The oxygen-carrying component may consist of any hemoglobin-based ox... | 09/05/2006 |
| 7041655 | Capillary membrane stabilization and reduction of tissue injury through use of IV biodegradable macromolecules with antioxidants and/or other chemicals In accordance with the invention there is provided a method of treating a human subject to prevent leakage of serum proteins from capillary endothelial junctions during a period of increased capillary permeability. The invention also provides a method for preventing... | 05/09/2006 |
| 6986905 | Pharmaceutical compositions for treating and saving and the method for the preparation thereof The present invention relates to a pharmaceutical composition and the method for the preparation thereof, The composition comprises 1.5˜6.9% (w/v) of one or more substances selected from sodium chloride, sodium bicarbonate, potassium chloride, magnesium sulfate, ca... | 01/17/2006 |
| 6599878 | Superoxygenating blood substitutes based on hemoglobin and dihydropyidine compositions The present invention provides superoxygenating compositions that comprise hemoglobin and guanosine 3':5'-cyclic monophosphate (cyclic GMP) generating compounds, and methods for treatment of diseases or medical conditions which utilize the superoxygenatin... | 07/29/2003 |
| 6562872 | Emulsion of perfluoroorganic compounds for medical purposes, a process for the preparation thereof and methods for treating and preventing diseases with the use thereof An emulsion of perfluoroorganic compounds (PFOC) comprises a rapidly eliminable perfluorocarbon (PFC) and a slowly eliminable perfluorinated cyclic tertiary amine, perfluoro-N-4-(methylcyclohexyl)-piperidine and additionally comprises not less then three ... | 05/13/2003 |
| 6432918 | Methods and compositions for optimization of oxygen transport by cell-free systems Compositions, and methods of use thereof, for use as blood substitute products comprise aqueous mixtures of oxygen-carrying and non-oxygen carrying plasma expanders and methods for the use thereof. The oxygen-carrying component may consist of any hemoglob... | 08/13/2002 |
| 6187744 | Methods and compositions for regulating the intravascular flow and oxygenating activity of hemoglobin in a human or animal subject Methods for time-regulated prophylaxis or treatment of animals or humans for limited circulatory oxygen delivery induced by the inhibitory effects of a plasma-borne hemoglobin-based material on L-arginine.fwdarw.nitric oxide.fwdarw.cGMP pathways in the ar... | 02/13/2001 |
| 6117838 | Use of hemoglobin in the treatment of hypotension A method of treating a mammal suffering from hypotension by administering intermolecularly- or intramolecularly-crosslinked stroma-free hemoglobin to the mammal.... | 09/12/2000 |
| 6113919 | Preparations comprising a fluorocarbon or a highly fluorinated compound and a lipophilic/fluorophilic compound and their uses Fluorocarbon emulsions comprising a stabilizing, particle size controlling fluorophilic/hydrophilic compound which can have the formula RF1 --W--RH1 (I) wherein RF1 is a lin... | 09/05/2000 |
| 6090779 | Use of hemoglobin to treat septic shock Therapeutic treatment of septic shock comprises administering to an animal stroma-free hemoglobin, typically at a dose ranging from the least amount effective to increase perfusion, up to a dosage of about 2500 milligrams kilograms per of body weight.... | 07/18/2000 |
| 6080397 | Compositions comprising PVP having an average molecular weight in the range of 3.000 to 14.000 daltons The present invention relates to compositions for use in medicine, e.g. as infusion or surgical rinse solutions, and to processes for their preparation. The compositions of the invention comprise an aqueous solution of physiologically inert PVP having a w... | 06/27/2000 |
| 6054427 | Methods and compositions for optimization of oxygen transport by cell-free systems Compositions, and methods of use thereof, for use as blood substitute products comprise aqueous mixtures of oxygen-carrying and non-oxygen carrying plasma expanders and methods for the use thereof. The oxygen-carrying component may consist of any hemoglob... | 04/25/2000 |
| 6046161 | Use of hemoglobin in the treatment of cardiogenic shock A method for increasing perfusion in a mammal suffering from cardiogenic shock by administering a perfusion-increasing effective amount of intermolecularly- or intramolecularly-crosslinked stroma-free hemoglobin to the mammal.... | 04/04/2000 |
| 6022850 | Use of hemoglobin in the treatment of stroke A method for increasing perfusion in a mammal suffering from stroke by admninistering a perfusion-increasing effective amount of intermolecularly- or intramolecularly-crosslinked stroma-free hemoglobin to the mammal.... | 02/08/2000 |
| 6020308 | Methods for improving therapeutic effectiveness of treatment of vascularization disorders The present invention is directed to the use of an inhibitor of NO activity, such as a nitric oxide scavenger or an NO synthase inhibitor, as as an adjunct to treatment of inappropriate tissue vascularization disorders.... | 02/01/2000 |
| 5927283 | Allosteric modifiers of hemoglobin A family of compounds has been found to be useful for right-shifting hemoglobin towards a low oxygen affinity state. The effect has particular application in a wide variety of treatments including hypoxia, hypothermia, ischemia, stroke, ARDS, COPD, surgic... | 07/27/1999 |
| 5869539 | Emulsions of perfluoro compounds as solvents for nitric oxide (NO) The present invention involves perfluoro compound emulsions including nitric oxide, their preparation and their use. These emulsions provide a new source of nitric oxide. Such nitric oxide-containing emulsions may be used for the administration of nitric ... | 02/09/1999 |
| 5785950 | Highly fluorinated, chloro-substituted organic compound-containing emulsions and methods of making and using them This invention relates to compositions comprising highly fluorinated, chloro-substituted, non-cyclic organic compounds having 7 to 9 carbon atoms and to processes of making and using them. More particularly, this invention relates to emulsions comprising ... | 07/28/1998 |
| 5776914 | Prevention of hemolysis Disclosed are compositions and methods for preventing or substantially inhibiting the hemolytic activity of hemolysis inducing agents. The methods and compositions are based on the use of an anionic oligosaccharide, such as polysulfated cyclodextrin, to a... | 07/07/1998 |
| 5733894 | Plasma-like substance An artificial plasma-like substance having at least one water soluble polysaccharide oncotic agent selected from the group consisting of high molecular weight hydroxyethyl starch, low molecular weight hydroxyethyl starch, dextran 40 and dextran 70, and al... | 03/31/1998 |
| 5705521 | Use of allosteric hemoglobin modifiers in combination with radiation therapy to treat carcinogenic tumors A family of compounds has been found to be useful for right-shifting hemoglobin towards a low oxygen affinity state. The effect has particular application in radiation oncology applications. The compounds are capable of acting on hemoglobin in whole blood... | 01/06/1998 |
| 5698536 | Plasma-like substance An artificial plasma-like substance having at least one water soluble polysaccharide oncotic agent selected from the group consisting of high molecular weight hydroxyethyl starch, low molecular weight hydroxyethyl starch, dextran 40 and dextran 70, and al... | 12/16/1997 |
| 5677330 | Medical uses of allosteric hemoglobin modifier compounds in patient care A family of compounds has been found to be useful for right-shifting hemoglobin towards a low oxygen affinity state. The effect has particular application in a wide variety of treatments including hypoxia, hypothermia, ischemia, stroke, ARDS, COPD, surgic... | 10/14/1997 |
| 5674913 | Method for assisting normal breathing in a mammal having a lung disorder A method of assisting a mammal having a lung disorder to breathe ambient gas normally, i.e., without the assistance of a ventilator. The method includes providing an animal having a lung disorder, such as surfactant deficiency, stiff lung or hyperinflated... | 10/07/1997 |
| 5661124 | Blood substitutes The present invention provides blood substitutes comprised of recombinantly produced mutant hemoglobin having an osmolarity greater than 303 milliosmoles per liter and less than 800 milliosmoles per liter. Such hyperosmolar blood substitute additionally c... | 08/26/1997 |
| 5661182 | Method for lowering oxygen affinity of hemoglobin in redcell suspensions, in whole blood and in vivo Drug compounds are used as allosteric modifiers of hemoglobin present in red blood cells. The compounds bind to only a single pair of symmetry related sites in the central water cavity of hemoglobin at the Lys 99, Arg 141, and Asn 108 ³... | 08/26/1997 |
| 5648375 | Use of hydrophobic compounds and anesthetics in combination with allosteric hemoglobin modifiers Allosteric hemoglobin modifier compound activity on p50 is potentiated by using the compound in combination with a hydrophobic compound such as an anesthetic.... | 07/15/1997 |
| 5635538 | Fluorocarbon emulsions with reduced pulmonary gas-trapping properties A fluorocarbon emulsion which exhibits reduced pulmonary gas-trapping properties in species-sensitive laboratory animals is disclosed. Additionally, the fluorocarbon component(s) exhibit short organ retention time(s). The emulsion includes an aqueous phas... | 06/03/1997 |
| 5613944 | Plasma-like substance An artificial plasma-like substance having at least one water soluble polysaccharide oncotic agent selected from the group consisting of high molecular weight hydroxyethyl starch, low molecular weight hydroxyethyl starch, dextran 40 and dextran 70, and al... | 03/25/1997 |
| 5612310 | Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders The present invention is directed to administration of a nitric oxide scavenger or a nitric oxide synthase inhibitor to enhance the effectiveness of tumor therapy with hypoxic or acidic chemotherapeutic agents or hyperthermia. In a specific example, admin... | 03/18/1997 |
| 5574019 | Method of perfusing a primate The present invention relates to the field of compositions of matter, disclosing compositions of matter which as aqueous solutions, may be used to perfuse a living or non-living subject in need of perfusion. The solutions according to the invention are ty... | 11/12/1996 |
| 5571801 | Plasma expander and blood substitute An artificial plasma-like substance having at least one water soluble polysaccharide oncotic agent selected from the group consisting of high molecular weight hydroxyethyl starch, low molecular weight hydroxyethyl starch, dextran 40 and dextran 70, and al... | 11/05/1996 |
| 5567765 | Physiologically acceptable emulsions containing perfluorocarbon ether hydrides and methods of use This invention relates to physiologically acceptable emulsions of perfluorocarbon ether hydrides having 8 to 12 carbon atoms. These novel emulsions have various medical applications. They are especially useful medically as contrast media for various biolo... | 10/22/1996 |
| 5525478 | Soluble thrombomodulin-based one-stage assay for vitamin-K dependent coagulation-inhibiting proteins The present invention provides a novel one-stage assay which uses soluble thrombomodulin for directly determining the functional status in plasma of the vitamin K-dependent coagulation-inhibiting proteins, protein C and protein S. The method comprises com... | 06/11/1996 |
| 5502043 | Use of hydroxyethyl starch for improvement of microcirculation The use of a hydroxyethyl starch specification with a molecular weight MW of 110,000 to 150,000, a substitution level MS of 0.38 to 0.5, a substitution level DS of 0.32 to 0.45, and a C2 /C6 ratio from 8 to 20 for improvem... | 03/26/1996 |
| 5498599 | Methods for stimulating platelet production Disclosed is a method for increasing the number of platelets in a mammal, which comprises administering to the mammal a platelet number increasing effective amount of an unbound, preferably a soluble, MPL receptor.... | 03/12/1996 |
| 5470841 | Metabolizable plasma substitute A metabolizable blood plasma substitute is described which contains a starch ester with a molecular weight (Mw) of>20000 Daltons and a molar substitution of 0.1 to 1.5 as a colloidal component. The starch ester is for example acetyl starch with a molecula... | 11/28/1995 |
| 5446030 | Prevention of hemolysis Disclosed are compositions and methods for prevented or substantially inhibiting the hemolytic activity of hemolysis inducing agents. The methods and compositions are based on the use an anionic oligosaccharide, such as polysulfated cyclodextrin, to achie... | 08/29/1995 |
| 5439944 | Red blood cell substitute emulsions containing alkyl- or alkylglyucerophosphoryl choline surfactants and methods of use Oil and water emulsions containing alkylphosphoryl choline or alkylglycerophosphoryl choline surfactants are disclosed. The surfactants have the following general structures: ##STR1## In the above general structures, R1, R2 or R... | 08/08/1995 |
